Supplementary Materials

Supplementary Material for:

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Yan Lan,* Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández, Molly H. Jenkins, Rachel E. Fontana, Amit Deshpande, George Locke, Helen Sabzevari, Laszlo Radvanyi, Kin-Ming Lo*

*Corresponding author. Email: yan.lan{at} (Y.L.); kinming.lo{at} (K.-M.L.)

Published 17 January 2018, Sci. Transl. Med. 10, eaan5488 (2018)
DOI: 10.1126/scitranslmed.aan5488

This PDF file includes:

  • Materials and Methods
  • Fig. S1. M7824 has a similar internalization rate as anti–PD-L1.
  • Fig. S2. M7824 lowers pSMAD2 in MC38 tumor–bearing mice.
  • Fig. S3. The trap control exhibits antitumor activity in vivo.
  • Fig. S4. M7824 inhibits tumor growth in individual mice in syngeneic tumor models.
  • Fig. S5. The trap control has about three times higher serum exposure than M7824.
  • Fig. S6. M7824 inhibits tumor growth in subcutaneous tumor models.
  • Fig. S7. M7824 inhibits tumor growth in wild-type mice.
  • Fig. S8. M7824 inhibits incidence of lung metastases relative to isotype control.
  • Fig. S9. M7824 increases mature DCs and EOMES-expressing CD8+ T cells in a dosage- and dosing frequency-dependent manner.
  • Fig. S10. M7824 induces an immunophenotypic signature in MC38 tumor–bearing wild-type mice.
  • Fig. S11. Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity.
  • Fig. S12. Combining M7824 with radiation enhances antitumor efficacy in individual mice.
  • Fig. S13. Neither anti–PD-L1 nor trap control significantly potentiated the abscopal effect of radiation.
  • Fig. S14. Combining M7824 with chemotherapy enhances antitumor efficacy in individual mice.
  • Table S1. Gene lists of immune signatures from differentially expressed gene analysis.
  • References (99105)

[Download PDF]